Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:AGK-BRAF (FusionGDB2 ID:HG55750TG673)

Fusion Gene Summary for AGK-BRAF

check button Fusion gene summary
Fusion gene informationFusion gene name: AGK-BRAF
Fusion gene ID: hg55750tg673
HgeneTgene
Gene symbol

AGK

BRAF

Gene ID

55750

673

Gene nameacylglycerol kinaseB-Raf proto-oncogene, serine/threonine kinase
SynonymsCATC5|CTRCT38|MTDPS10|MULKB-RAF1|B-raf|BRAF1|NS7|RAFB1
Cytomap('AGK')('BRAF')

7q34

7q34

Type of geneprotein-codingprotein-coding
Descriptionacylglycerol kinase, mitochondrialhAGKhsMuLKmulti-substrate lipid kinasemultiple substrate lipid kinaseserine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene
Modification date2020031320200329
UniProtAcc.

P15056

Ensembl transtripts involved in fusion geneENST00000495028, ENST00000473247, 
ENST00000355413, ENST00000492693, 
ENST00000535825, 		ENST00000492693, 
ENST00000495028, ENST00000535825, 
ENST00000355413, ENST00000473247, 
Fusion gene scores* DoF score6 X 5 X 6=18048 X 58 X 16=44544
# samples 869
** MAII scorelog2(8/180*10)=-1.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(69/44544*10)=-6.0124909441832
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: AGK [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointAGK(141255367)-BRAF(140494267), # samples:3
Anticipated loss of major functional domain due to fusion event.AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BRAF-AGK seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BRAF-AGK seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
AGK-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
AGK-BRAF seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
AGK-BRAF seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
AGK-BRAF seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneAGK

GO:0045039

protein import into mitochondrial inner membrane

28712724|28712726

TgeneBRAF

GO:0000186

activation of MAPKK activity

29433126

TgeneBRAF

GO:0006468

protein phosphorylation

17563371

TgeneBRAF

GO:0010828

positive regulation of glucose transmembrane transport

23010278

TgeneBRAF

GO:0033138

positive regulation of peptidyl-serine phosphorylation

19667065

TgeneBRAF

GO:0043066

negative regulation of apoptotic process

19667065

TgeneBRAF

GO:0070374

positive regulation of ERK1 and ERK2 cascade

22065586

TgeneBRAF

GO:0071277

cellular response to calcium ion

18567582

TgeneBRAF

GO:0090150

establishment of protein localization to membrane

23010278


check buttonFusion gene breakpoints across AGK (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure
check buttonFusion gene breakpoints across BRAF (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check button Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4SKCMTCGA-DA-A1IA-06AAGKchr7

141255367

-BRAFchr7

140494267

-
ChimerDB4SKCMTCGA-DA-A1IA-06AAGKchr7

141255367

+BRAFchr7

140494267

-
ChimerDB4THCATCGA-DJ-A2PX-01AAGKchr7

141255367

-BRAFchr7

140494267

-
ChimerKB4..AGKchr7

141255252

+BRAFchr7

141255252

-


Top

Fusion Gene ORF analysis for AGK-BRAF

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
3UTR-3CDSENST00000495028ENST00000288602AGKchr7

141255367

+BRAFchr7

140494267

-
Frame-shiftENST00000473247ENST00000288602AGKchr7

141255367

+BRAFchr7

140494267

-
In-frameENST00000355413ENST00000288602AGKchr7

141255367

+BRAFchr7

140494267

-
In-frameENST00000492693ENST00000288602AGKchr7

141255367

+BRAFchr7

140494267

-
In-frameENST00000535825ENST00000288602AGKchr7

141255367

+BRAFchr7

140494267

-
intron-intronENST00000355413ENST00000288602AGKchr7

141255252

+BRAFchr7

141255252

-
intron-intronENST00000473247ENST00000288602AGKchr7

141255252

+BRAFchr7

141255252

-
intron-intronENST00000492693ENST00000288602AGKchr7

141255252

+BRAFchr7

141255252

-
intron-intronENST00000495028ENST00000288602AGKchr7

141255252

+BRAFchr7

141255252

-
intron-intronENST00000535825ENST00000288602AGKchr7

141255252

+BRAFchr7

141255252

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000355413AGKchr7141255367+ENST00000288602BRAFchr7140494267-18003612601681473
ENST00000535825AGKchr7141255367+ENST00000288602BRAFchr7140494267-1579140391460473
ENST00000492693AGKchr7141255367+ENST00000288602BRAFchr7140494267-1554115141435473

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000355413ENST00000288602AGKchr7141255367+BRAFchr7140494267-0.0059536970.99404633
ENST00000535825ENST00000288602AGKchr7141255367+BRAFchr7140494267-0.0034125080.9965875
ENST00000492693ENST00000288602AGKchr7141255367+BRAFchr7140494267-0.0028837150.9971163

Top

Fusion Genomic Features for AGK-BRAF


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.
genomic feature

Top

Fusion Protein Features for AGK-BRAF


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:141255367/chr7:140494267)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.BRAF

P15056

FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneAGKchr7:141255367chr7:140494267ENST00000355413+21615_3133423.0RegionHydrophobic
HgeneAGKchr7:141255367chr7:140494267ENST00000492693+1315_313366.0RegionHydrophobic
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618428_432326767.0Compositional biasNote=Poly-Ser
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618457_717326767.0DomainProtein kinase
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618463_471326767.0Nucleotide bindingATP

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneAGKchr7:141255367chr7:140494267ENST00000355413+21658_19933423.0DomainDAGKc
HgeneAGKchr7:141255367chr7:140494267ENST00000492693+1358_1993366.0DomainDAGKc
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618122_129326767.0Compositional biasNote=Poly-Ser
TgeneBRAFchr7:141255367chr7:140494267ENST000002886026186_11326767.0Compositional biasNote=Poly-Gly
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618155_227326767.0DomainRBD
TgeneBRAFchr7:141255367chr7:140494267ENST00000288602618234_280326767.0Zinc fingerPhorbol-ester/DAG-type


Top

Fusion Gene Sequence for AGK-BRAF


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>2885_2885_1_AGK-BRAF_AGK_chr7_141255367_ENST00000355413_BRAF_chr7_140494267_ENST00000288602_length(transcript)=1800nt_BP=361nt
ATGAAAGGAAGAGTGAGCCAATAAACGAGGGAACGCCGGGAAAGGCAGCCTCAAGCCGGTGGGCCCTGCCACCCCCACCGTCCCTGAGCA
TCCGAGCCGGTTCCCGCCCCCGGCCCGAACTGGCCCGCGCGCGCTCGCAGCCCCGCGGCGGAACCCGAGGGCGGCGGCAGCGGTTTCCCT
TGAACGAGCCGGGGAATCTGGAGGGAGCACACAGGAAAGGCAGAGCCGCGAGCTGGACCAGCCGTGCAAATCTCTAGAAGATGACGGTGT
TCTTTAAAACGCTTCGAAATCACTGGAAGAAAACTACAGCTGGGCTCTGCCTGCTGACCTGGGGAGGCCATTGGCTCTATGGAAAACACT
GGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCATTCCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAAT
TTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCATATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAG
GATTTCGTGGTGATGGAGGATCAACCACAGGTTTGTCTGCTACCCCCCCTGCCTCATTACCTGGCTCACTAACTAACGTGAAAGCCTTAC
AGAAATCTCCAGGACCTCAGCGAGAAAGGAAGTCATCTTCATCCTCAGAAGACAGGAATCGAATGAAAACACTTGGTAGACGGGACTCGA
GTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGTGGC
ATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCAGGA
AAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCAGCT
TGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGACAGACTGCACAGGGCATGGATTACT
TACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTC
TAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCAGAA
TGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTTATT
CAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTCCAA
AAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGCTGC
TGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTATATG
CTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGAGAG
TAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAATTGAATAAAATACTCTCTTTTTTTTTAAGGTGAACCAAAGAA

>2885_2885_1_AGK-BRAF_AGK_chr7_141255367_ENST00000355413_BRAF_chr7_140494267_ENST00000288602_length(amino acids)=473AA_BP=34
MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHWPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLI
RDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYK
GKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQG
MDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQ
LPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDF

--------------------------------------------------------------
>2885_2885_2_AGK-BRAF_AGK_chr7_141255367_ENST00000492693_BRAF_chr7_140494267_ENST00000288602_length(transcript)=1554nt_BP=115nt
CAAATCTCTAGAAGATGACGGTGTTCTTTAAAACGCTTCGAAATCACTGGAAGAAAACTACAGCTGGGCTCTGCCTGCTGACCTGGGGAG
GCCATTGGCTCTATGGAAAACACTGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCATTCCAATTCCACAGCCCTTCCGACCAG
CAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCATATAAACACAATAGAACCTGTCAATA
TTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGGATCAACCACAGGTTTGTCTGCTACCCCCCCTGCCTCATTACCTGGCT
CACTAACTAACGTGAAAGCCTTACAGAAATCTCCAGGACCTCAGCGAGAAAGGAAGTCATCTTCATCCTCAGAAGACAGGAATCGAATGA
AAACACTTGGTAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTG
GAACAGTCTACAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCA
AAAATGAAGTAGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTA
CCCAGTGGTGTGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGAC
AGACTGCACAGGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCA
CAGTAAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGT
GGATGGCACCAGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAAT
TGATGACTGGACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCA
GTAAGGTACGGAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCC
AAATTCTCGCCTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCC
AAACAGAGGATTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACA
AATGAGTGAGAGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAATTGAATAAAATACTCTCT

>2885_2885_2_AGK-BRAF_AGK_chr7_141255367_ENST00000492693_BRAF_chr7_140494267_ENST00000288602_length(amino acids)=473AA_BP=34
MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHWPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLI
RDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYK
GKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQG
MDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQ
LPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDF

--------------------------------------------------------------
>2885_2885_3_AGK-BRAF_AGK_chr7_141255367_ENST00000535825_BRAF_chr7_140494267_ENST00000288602_length(transcript)=1579nt_BP=140nt
AGAGCCGCGAGCTGGACCAGCCGTGCAAATCTCTAGAAGATGACGGTGTTCTTTAAAACGCTTCGAAATCACTGGAAGAAAACTACAGCT
GGGCTCTGCCTGCTGACCTGGGGAGGCCATTGGCTCTATGGAAAACACTGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCATT
CCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCAT
ATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGGATCAACCACAGGTTTGTCTGCT
ACCCCCCCTGCCTCATTACCTGGCTCACTAACTAACGTGAAAGCCTTACAGAAATCTCCAGGACCTCAGCGAGAAAGGAAGTCATCTTCA
TCCTCAGAAGACAGGAATCGAATGAAAACACTTGGTAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGA
CAAAGAATTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCT
ACACCTCAGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCC
ACAAAGCCACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATG
ATCAAACTTATAGATATTGCACGACAGACTGCACAGGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAAT
AATATATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTT
GAACAGTTGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATAT
GCATTTGGAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGA
CGAGGATACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAA
AGAGATGAGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAA
CCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATAT
GGTGCGTTTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATA

>2885_2885_3_AGK-BRAF_AGK_chr7_141255367_ENST00000535825_BRAF_chr7_140494267_ENST00000288602_length(amino acids)=473AA_BP=34
MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHWPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLI
RDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYK
GKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQG
MDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQ
LPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDF

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for AGK-BRAF


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for AGK-BRAF


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
TgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational

Top

Related Diseases for AGK-BRAF


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneAGKC1859317Cataract and cardiomyopathy4CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneAGKC0266539Congenital total cataract2ORPHANET
HgeneAGKC3553494CATARACT 381CTD_human;GENOMICS_ENGLAND
TgeneC0025202melanoma24CGI;CTD_human;UNIPROT
TgeneC1275081Cardio-facio-cutaneous syndrome14CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneC0009402Colorectal Carcinoma8CTD_human;UNIPROT
TgeneC0028326Noonan Syndrome8CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneC0238463Papillary thyroid carcinoma8CTD_human;ORPHANET
TgeneC0040136Thyroid Neoplasm6CGI;CTD_human
TgeneC0151468Thyroid Gland Follicular Adenoma6CTD_human
TgeneC0175704LEOPARD Syndrome6CLINGEN;GENOMICS_ENGLAND
TgeneC0549473Thyroid carcinoma6CGI;CTD_human
TgeneC3150970NOONAN SYNDROME 75CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneC0009404Colorectal Neoplasms4CTD_human
TgeneC3150971LEOPARD SYNDROME 34CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneC1519086Pilomyxoid astrocytoma3ORPHANET
TgeneC0004565Melanoma, B162CTD_human
TgeneC0009075Melanoma, Cloudman S912CTD_human
TgeneC0018598Melanoma, Harding-Passey2CTD_human
TgeneC0023443Hairy Cell Leukemia2CGI;ORPHANET
TgeneC0025205Melanoma, Experimental2CTD_human
TgeneC0033578Prostatic Neoplasms2CTD_human
TgeneC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
TgeneC0376358Malignant neoplasm of prostate2CTD_human
TgeneC0587248Costello syndrome (disorder)2CLINGEN;CTD_human
TgeneC3501843Nonmedullary Thyroid Carcinoma2CTD_human
TgeneC3501844Familial Nonmedullary Thyroid Cancer2CTD_human
TgeneC0002448Ameloblastoma1CTD_human
TgeneC0004114Astrocytoma1CTD_human
TgeneC0010276Craniopharyngioma1CTD_human;ORPHANET
TgeneC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
TgeneC0017638Glioma1CGI;CTD_human
TgeneC0019621Histiocytosis, Langerhans-Cell1CGI;ORPHANET
TgeneC0022665Kidney Neoplasm1CTD_human
TgeneC0023903Liver neoplasms1CTD_human
TgeneC0024232Lymphatic Metastasis1CTD_human
TgeneC0024694Mandibular Neoplasms1CTD_human
TgeneC0027659Neoplasms, Experimental1CTD_human
TgeneC0027962Melanocytic nevus1GENOMICS_ENGLAND
TgeneC0036920Sezary Syndrome1CTD_human
TgeneC0041409Turner Syndrome, Male1CTD_human
TgeneC0079773Lymphoma, T-Cell, Cutaneous1CTD_human
TgeneC0205768Subependymal Giant Cell Astrocytoma1CTD_human
TgeneC0206686Adrenocortical carcinoma1CTD_human
TgeneC0206754Neuroendocrine Tumors1CTD_human
TgeneC0259783mixed gliomas1CTD_human
TgeneC0278875Adult Craniopharyngioma1CTD_human
TgeneC0280783Juvenile Pilocytic Astrocytoma1CTD_human
TgeneC0280785Diffuse Astrocytoma1CTD_human
TgeneC0334579Anaplastic astrocytoma1CGI;CTD_human
TgeneC0334580Protoplasmic astrocytoma1CTD_human
TgeneC0334581Gemistocytic astrocytoma1CTD_human
TgeneC0334582Fibrillary Astrocytoma1CTD_human
TgeneC0334583Pilocytic Astrocytoma1CGI;CTD_human
TgeneC0338070Childhood Cerebral Astrocytoma1CTD_human
TgeneC0345904Malignant neoplasm of liver1CTD_human
TgeneC0376407Granulomatous Slack Skin1CTD_human
TgeneC0406803Syringocystadenoma Papilliferum1GENOMICS_ENGLAND
TgeneC0431128Papillary craniopharyngioma1CTD_human
TgeneC0431129Adamantinous Craniopharyngioma1CTD_human
TgeneC0547065Mixed oligoastrocytoma1CTD_human
TgeneC0555198Malignant Glioma1CTD_human
TgeneC0596263Carcinogenesis1CTD_human
TgeneC0684249Carcinoma of lung1CGI;UNIPROT
TgeneC0740457Malignant neoplasm of kidney1CTD_human
TgeneC0750935Cerebral Astrocytoma1CTD_human
TgeneC0750936Intracranial Astrocytoma1CTD_human
TgeneC0751061Craniopharyngioma, Child1CTD_human
TgeneC0920269Microsatellite Instability1CTD_human
TgeneC1527404Female Pseudo-Turner Syndrome1CTD_human
TgeneC1704230Grade I Astrocytoma1CTD_human
TgeneC1721098Replication Error Phenotype1CTD_human
TgeneC2239176Liver carcinoma1CTD_human
TgeneC4551484Leopard Syndrome 11GENOMICS_ENGLAND
TgeneC4551602Noonan Syndrome 11CTD_human
TgeneC4721532Lymphoma, Non-Hodgkin, Familial1UNIPROT
TgeneC4733333familial non-medullary thyroid cancer1GENOMICS_ENGLAND